Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance - The BMJ

Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance - The BMJ

Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance - The BMJ

Posted: 29 Jul 2019 03:22 AM PDT

  1. Nicholas S Hopkinson, reader in respiratory medicine and honorary consultant physician1,
  2. Andrew Molyneux, consultant physician in respiratory and medicine and chair of Guideline Committee2,
  3. Joshua Pink, technical advisor3,
  4. Marie C Harrisingh, senior technical analyst3
  5. on behalf of the Guideline Committee (GC)
  1. 1National Heart and Lung Institute, Imperial College, London, UK
  2. 2Sherwood Forest Hospitals NHS Foundation Trust, Nottinghamshire, UK
  3. 3National Institute for Health and Care Excellence, London, UK
  1. Correspondence to M Harrisingh marie.harrisingh{at}nice.org.uk

What you need to know

  • The interventions of highest value for people with chronic obstructive pulmonary disease (COPD) are treatment and support to stop smoking, pulmonary rehabilitation in patients limited by breathlessness, and flu vaccination

  • Choice of initial long acting inhaled therapies depends on the presence or absence of asthmatic features/features which suggest steroid responsiveness

  • Self management plans improve quality of life and reduce hospital admissions

  • Treatment for acute exacerbations of COPD, including rescue packs for patients to use for self management, should be for five days only

  • Only prescribe home oxygen for people who are hypoxic and do not smoke currently

There are 1.3 million people in the UK with a diagnosis of chronic obstructive pulmonary disease (COPD) and the condition is responsible for considerable morbidity and mortality.1 COPD is also a common cause of hospital admission. NHS England has now recognised respiratory disease as a priority area in the Long Term Plan,2 but Royal College of Physicians COPD Audits3 identify substantial deficiencies across the healthcare system, including marked under-provision of pulmonary rehabilitation, flu vaccination, and smoking cessation treatment.

This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE).10 The updated areas are mainly concerned with the management of stable COPD and include self management and education, assessment for lung volume reduction procedures, and home oxygen use. This article focuses on the newly updated sections, with reference to older recommendations where they are particularly important or needed for context.

Effective COPD management pathways require an integrated approach across primary and secondary care and involve a multidisciplinary team of health professionals. The guidance focuses on the need to ensure that good quality care is delivered wherever patients are seen. Specialist care, whether delivered in a hospital or community setting, may be indicated for people …

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more